Tags:CauseDrugFastMarketProductPropertyUniversity
Treating Diabetic and Rare Kidney Disease XORTX is a therapeutics company spun out from the University of Florida, with a fast track strategy to licensing and market approval. Initially targeting the orphan disease markets, we are developing safer therapies to treat major and rare kidney diseases caused by improper uric acid metabolism. Uric acid is an essential molecule necessary for excretion of excess nutrients. However, at chronically high levels, serum uric acid (SUA) acts through a newly discovered mechanism to cause disease. XORTX is focusing on new applications of selected drug products that treat rare diseases like autosomal dominant polycystic kidney disease (ADPKD) and lifestyle diseases like metabolic syndrome, diabetes and diabetic nephropathy, which had previously not been associated with high SUA. XORTX has secured intellectual property and experienced key personnel to exploit the therapeutic potential of drugs to decrease SUA levels. Orphan programs are attractive due to market exclusivity and price benefits.
Total raised: $17M

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
07.10.2022-$5M-globenewsw...
13.10.2021-$12M-globenewsw...

Mentions in press and media 50

DateTitleDescriptionCategoryAuthorSource
07.10.2022XORTX Anno.../EIN News/ -- CALGARY, Alberta...--einpresswi...
07.10.2022XORTX Anno...CALGARY, Alberta, Oct. 07, 202...--globenewsw...
04.10.2022XORTX Anno.../EIN News/ -- CALGARY, Alberta...--einpresswi...
04.10.2022XORTX Anno...CALGARY, Alberta, Oct. 04, 202...--globenewsw...
19.09.2022XORTX Comp...CALGARY, Alberta, Sept. 19, 20...--globenewsw...
01.09.2022XORTX Spon...CALGARY, Alberta, Sept. 01, 20...--globenewsw...
22.08.2022XORTX Anno...CALGARY, Alberta, Aug. 22, 202...--globenewsw...
04.08.2022XORTX Anno...CALGARY, Alberta, Aug. 04, 202...--globenewsw...
22.07.2022XORTX Repo...CALGARY, Alberta, July 22, 202...--globenewsw...
19.07.2022XORTX Anno...CALGARY, Alberta, July 19, 202...--globenewsw...
Show more